Alpine Immune Sciences, Inc. (NASDAQ:ALPN – Free Report) – Equities researchers at Wedbush raised their FY2023 earnings per share estimates for Alpine Immune Sciences in a note issued to investors on Wednesday, November 15th. Wedbush analyst R. Driscoll now anticipates that the biotechnology company will earn ($0.96) per share for the year, up from their previous forecast of ($1.02). Wedbush currently has a “Outperform” rating and a $26.00 target price on the stock. The consensus estimate for Alpine Immune Sciences’ current full-year earnings is ($1.24) per share. Wedbush also issued estimates for Alpine Immune Sciences’ Q2 2024 earnings at ($0.20) EPS, Q3 2024 earnings at ($0.21) EPS, Q4 2024 earnings at ($0.34) EPS, FY2024 earnings at ($0.96) EPS, FY2025 earnings at ($1.38) EPS and FY2026 earnings at ($1.49) EPS.
Alpine Immune Sciences (NASDAQ:ALPN – Get Free Report) last released its quarterly earnings results on Monday, August 14th. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.38) by $0.11. The company had revenue of $8.59 million for the quarter, compared to analysts’ expectations of $8.08 million. Alpine Immune Sciences had a negative net margin of 185.10% and a negative return on equity of 33.53%.
Alpine Immune Sciences Price Performance
NASDAQ:ALPN opened at $12.66 on Friday. Alpine Immune Sciences has a 1-year low of $5.81 and a 1-year high of $16.26. The firm has a 50 day simple moving average of $11.47 and a 200-day simple moving average of $11.24.
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in ALPN. Bank of New York Mellon Corp grew its stake in shares of Alpine Immune Sciences by 1.3% in the third quarter. Bank of New York Mellon Corp now owns 92,723 shares of the biotechnology company’s stock valued at $1,062,000 after buying an additional 1,216 shares in the last quarter. Royal Bank of Canada grew its position in Alpine Immune Sciences by 99.1% in the second quarter. Royal Bank of Canada now owns 2,642 shares of the biotechnology company’s stock valued at $27,000 after acquiring an additional 1,315 shares in the last quarter. American International Group Inc. grew its position in Alpine Immune Sciences by 26.8% in the second quarter. American International Group Inc. now owns 7,310 shares of the biotechnology company’s stock valued at $62,000 after acquiring an additional 1,543 shares in the last quarter. JPMorgan Chase & Co. raised its stake in shares of Alpine Immune Sciences by 23.4% during the first quarter. JPMorgan Chase & Co. now owns 8,947 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 1,697 shares during the period. Finally, California State Teachers Retirement System lifted its position in shares of Alpine Immune Sciences by 20.0% during the second quarter. California State Teachers Retirement System now owns 10,559 shares of the biotechnology company’s stock worth $109,000 after purchasing an additional 1,763 shares in the last quarter. 75.17% of the stock is owned by hedge funds and other institutional investors.
Insider Transactions at Alpine Immune Sciences
In other Alpine Immune Sciences news, insider James Paul Rickey sold 18,003 shares of Alpine Immune Sciences stock in a transaction that occurred on Monday, November 6th. The shares were sold at an average price of $16.03, for a total transaction of $288,588.09. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 42.30% of the company’s stock.
About Alpine Immune Sciences
Alpine Immune Sciences, Inc operates as a clinical-stage immunotherapy company. It focuses on creating various immunotherapies through protein engineering technologies for autoimmune and inflammatory diseases. The company has strategic collaborations with biopharmaceutical companies and has a pipeline of clinical and preclinical candidates in development.
- Five stocks we like better than Alpine Immune Sciences
- Investing in Commodities: What Are They? How to Invest in Them
- Williams-Sonoma is a steal for buy-and-hold investors
- Investing in Blue-Chip Stocks
- A closer look at Warren Buffett’s latest surprise purchase
- Investing In Automotive Stocks
- GE stock surges to six-year high: What’s behind the move?
Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.